Arete Wealth Advisors LLC purchased a new position in Altimmune, Inc. (NASDAQ:ALT – Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 28,427 shares of the company’s stock, valued at approximately $322,000. Arete Wealth Advisors LLC owned about 0.06% of Altimmune at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Boulder Hill Capital Management LP acquired a new position in Altimmune during the first quarter valued at approximately $50,000. Graham Capital Management L.P. acquired a new position in Altimmune during the first quarter valued at approximately $63,000. Pitcairn Co. acquired a new position in Altimmune during the first quarter valued at approximately $69,000. Charles Schwab Investment Management Inc. grew its holdings in Altimmune by 18.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 20,396 shares of the company’s stock valued at $86,000 after purchasing an additional 3,122 shares during the period. Finally, Engineers Gate Manager LP acquired a new position in Altimmune during the first quarter valued at approximately $87,000. 66.99% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
ALT has been the topic of several research reports. HC Wainwright decreased their price target on shares of Altimmune from $50.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, August 14th. B. Riley reduced their price target on shares of Altimmune from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.20.
Altimmune Stock Up 4.7 %
Shares of ALT stock opened at $2.92 on Monday. The firm has a market capitalization of $153.85 million, a price-to-earnings ratio of -1.79 and a beta of -0.03. The stock has a fifty day moving average of $2.88 and a 200 day moving average of $4.47. Altimmune, Inc. has a 52 week low of $2.34 and a 52 week high of $17.17.
Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.12. The firm had revenue of $0.01 million for the quarter. Equities research analysts anticipate that Altimmune, Inc. will post -1.6 earnings per share for the current year.
Altimmune Company Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
- Five stocks we like better than Altimmune
- What is Forex and How Does it Work?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Your Comprehensive Guide to Investing in Bank Stocks
- MarketBeat Week in Review – 9/11 – 9/15
- How to Buy Cheap Stocks Step by Step
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.